NEW YORK (GenomeWeb) – Interpace Diagnostics today reported a 60 percent increase in second quarter revenues, in part due to increased reimbursement for its ThyraMir and ThyraGenX thyroid cancer tests.

For the three-month period ended June 30, Interpace's revenues climbed to $3.6 million from $2.3 million in the same quarter last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.